Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study investigates cholesterol side effect of diabetes drug

NCT ID NCT03269058

First seen Mar 21, 2026 · Last updated May 01, 2026 · Updated 4 times

Summary

This study aims to understand why dapagliflozin, a diabetes medication, can increase bad cholesterol levels. Researchers will track how the body produces and removes cholesterol in 28 adults with type 2 diabetes over 6 months. Half will receive the drug, half a placebo. The results may help doctors choose better cholesterol treatments for these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Dijon Bourgogne

    Dijon, 21079, France

Conditions

Explore the condition pages connected to this study.